Identifying two distinct cortical progression subtypes of Parkinson's disease through multimodal neuroimaging
Parkinson's disease follows two distinct progression patterns, potentially enabling personalized treatment strategies in future trials.
Using FDG-PET and MRI with data-driven SuStaIn modeling in 317 PD patients, two distinct cortical progression patterns were identified and externally validated in PPMI data, revealing substantial phenotypic heterogeneity in Parkinson's disease. This disease stratification framework may inform future personalized clinical trial design and biomarker-driven subgroup analysis.
What the study was
- Study design
- Cross-sectional multimodal imaging study with external validation (PPMI dataset)
- Population
- Parkinson's disease patients (n=317) and healthy controls (n=61); external validation in PPMI dataset
- Sample size
- 378
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
Why it surfaced
Cross-sectional multimodal imaging with PPMI external validation; SuStaIn model provides rigorous disease staging; clinically relevant heterogeneity characterization for PD trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.